コンパニオン診断薬市場：技術、適応症、エンドユーザー別-世界予測2024-2030年

コンパニオン診断薬市場規模は、2023年に66億4,000万米ドルと推計され、2024年には73億米ドルに達し、CAGR 10.65%で2030年には134億9,000万米ドルに達すると予測されています。

コンパニオン診断薬は、ヘルスケア専門家が特定の医療処置が患者に有効かどうかを判断したり、その個人に最適な投薬量を特定したりするのに役立つように設計された特殊な検査です。これらの検査は個別化医療に不可欠な要素であり、ライフスタイル、遺伝的体質、環境など、患者一人ひとりの特性に合わせた治療を行う医療アプローチです。コンパニオン診断薬は、特に特定のがんの管理に広く用いられており、腫瘍内に存在する遺伝子変化によって治療効果が大きく左右されることがあります。治療が個々の患者プロファイルに最適化される個別化医療への推進が、コンパニオン診断薬の需要を大きく牽引しています。さらに、特に腫瘍学における標的治療の開発には、これらの治療から最も恩恵を受ける患者を特定するためのコンパニオン診断薬が必要です。しかし、コンパニオン診断薬の開発と導入にはコストがかかり、不十分な償還が大きな障壁となっています。さらに、次世代シークエンシングやデジタルPCRなどの技術がコンパニオン診断薬の機能を拡張し、より包括的な遺伝子プロファイリングを可能にしており、市場成長の大きな機会となっています。

テクノロジー精密医療における次世代シーケンサーの選好の高まり

免疫組織化学（IHC）は、組織切片細胞中のタンパク質を検出することで病気を診断するために用いられる技術です。がんの種類や治療に対する潜在的な反応性を判断するのに役立つ特異的マーカーを同定するために、がん診断に広く用いられています。診断の焦点が組織サンプル中のタンパク質発現の局在と質的評価にある場合には、IHCが好まれます。Situ Hybridization（ISH）は、組織切片または細胞サンプル中の特定のDNAまたはRNA配列の検出と局在化を可能にし、遺伝子発現と染色体異常に関する洞察を提供します。この技術は、特定のがんに関連する特定の遺伝子再配列や増幅を検出する上で特に有用です。次世代シーケンサー（NGS）は、前例のないスピードとスケールで全ゲノムまたは目的の領域のシーケンシングを可能にすることで、遺伝子構成に関する包括的な洞察を提供します。NGSは、様々な疾患における標的治療の選択に関連する可能性のある小さな変異、コピー数の変異などを含む遺伝的変異の広範な理解を必要とするアプリケーションに選択される技術です。ポリメラーゼ連鎖反応（PCR）は、DNAまたはRNAの小さなセグメントを強化するために利用される技術であり、さらなる分析を容易にします。PCRはその簡便さ、感度、特異性から最も広く使われている技術の一つです。PCRは、その迅速な処理時間から非常に好まれており、治療法選択のための迅速な意思決定を必要とする疾患に理想的です。

エンドユーザー製薬・バイオ医薬品分野の拡大がコンパニオン診断薬の重要性を牽引

主に治療薬の発見、開発、商業化に携わる製薬・バイオ医薬品企業。コンパニオン診断薬の統合は、特にがん治療を含む標的治療薬の開発プロセスにおいて極めて重要です。これらの企業は治療に対する反応をモニターし、必要に応じて治療計画を調整するためにコンパニオン診断薬を必要としています。レファレンス・ラボラトリーは、複雑で高度な診断検査を実施する専門施設であり、多くの場合、標準的な病院のラボでは利用できないです。特定の疾患や治療反応に関連するバイオマーカーの同定に役立つ複雑性の高い検査を提供することで、コンパニオン診断薬の実施において重要な役割を果たしています。

地域別インサイト

南北アメリカでは、コンパニオン診断薬の需要は、強固なヘルスケアインフラ、個別化医療に対する意識の高まり、重要な研究開発活動によって牽引されています。米国食品医薬品局（FDA）は、特にがん治療に対するコンパニオン診断薬の承認に積極的であり、治療方針の決定におけるこれらのツールの重要性が強調されています。この地域での投資やイニシアチブは、主にがん、心血管疾患、神経学に集中しており、個別化ヘルスケアソリューションへの広範な傾向を反映しています。EU諸国はコンパニオン診断薬に対する高い需要を示しており、患者の安全性を確保しながらイノベーションを促進する強力な規制の枠組みに支えられています。欧州医薬品庁（EMA）は、欧州全域におけるコンパニオン診断薬の承認において重要な役割を果たしています。EUの消費者ニーズは洗練されており、個別化されたヘルスケアサービスへの期待が高いです。アラブ首長国連邦やサウジアラビアなどの中東諸国では、個別化医療への関心が高まっており、これは政府の取り組みやヘルスケア・インフラへの投資に支えられています。しかし、アフリカは医療インフラやアクセスが限られているため、大きなハードルに直面しています。APACでは、医療水準の向上と個別化医療の普及を目指す政府のイニシアチブに後押しされ、コンパニオン診断薬市場が急速に拡大しています。政府は、遺伝子調査への多額の投資など、精密医療を推進するためのイニシアチブをいくつか打ち出しています。このような焦点は、特に医療設備の整った都市部において、コンパニオン診断薬の需要拡大に徐々に反映されつつあります。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはコンパニオン診断薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、コンパニオン診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.コンパニオン診断薬市場の市場規模および予測は？

2.コンパニオン診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.コンパニオン診断薬市場の技術動向と規制枠組みは？

4.コンパニオン診断薬市場における主要ベンダーの市場シェアは？

5.コンパニオン診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医薬品開発におけるコンパニオン診断薬の重要性の高まり
    • 個別化医薬品と標的療法の需要増加
    • 次世代シーケンシングの革新に向けた研究開発の高まり
  • 抑制要因
    • コンパニオン診断薬の開発と実装に関連する高コスト
  • 機会
    • 診断技術における継続的な技術的進歩
    • コンパニオン診断薬の開発と承認を促進する有利な規制政策
  • 課題
    • コンパニオン診断検査に関連する償還問題
• 市場セグメンテーション分析
  • テクノロジー：精密医療における次世代シーケンシングの好感度が増加
  • エンドユーザー：製薬およびバイオ医薬品セクターの拡大がコンパニオン診断薬の重要性を推進
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 コンパニオン診断薬市場：技術別

• 免疫組織化学
• インサイチューハイブリダイゼーション
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 コンパニオン診断薬市場適応症別

• がん
• 心血管疾患
• 感染症
• 神経学的障害

第8章 コンパニオン診断薬市場：エンドユーザー別

• 製薬・バイオ医薬品企業
• リファレンスラボ

第9章 南北アメリカのコンパニオン診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のコンパニオン診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのコンパニオン診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • サーモフィッシャーサイエンティフィックとバイエルの革新的な提携により、精密がん治療の新たな基準が確立
  • アジレントと洞察の戦略的提携によりコンパニオン診断の開発が促進される
  • 新たな治療の展望を開く：FDAが進行性乳がんに対するCapivasertibとフルベストラントの併用を承認、FoundationOne（R）CDx診断の進歩を支援
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 67. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 68. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 69. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 70. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 71. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 74. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 75. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 81. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 82. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 83. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 84. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 91. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 94. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 104. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 109. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 110. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 111. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 112. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 113. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 114. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 115. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 116. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 117. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 118. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 119. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 120. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 121. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 122. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 123. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 126. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 127. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 128. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 133. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 134. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 135. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 141. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 142. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 143. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 144. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 150. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 151. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 152. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 157. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 158. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 159. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 165. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 166. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 167. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 168. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 176. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 181. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 182. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 183. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 184. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 189. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 190. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 191. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 197. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 198. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 199. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 200. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 215. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 216. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 217. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 218. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 224. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 225. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 226. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 231. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 232. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 233. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 239. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 240. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 241. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 242. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 248. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 249. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 250. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 255. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 256. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 257. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 258. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 259. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 260. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 261. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 262. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 263. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 264. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 265. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 266. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 267. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 268. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 271. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 272. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 273. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 274. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 275. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 276. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 279. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 280. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 281. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 284. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 287. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 288. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 289. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 290. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 291. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 292. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 293. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 294. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 295. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 296. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 297. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 298. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 299. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 300. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 301. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 302. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 303. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 304. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 305. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 306. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 307. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 308. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 309. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 310. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 311. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 312. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 313. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 314. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 316. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 317. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 318. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 319. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 320. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 321. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 322. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 324. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 325. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 326. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 327. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 328. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 329. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 330. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 331. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 332. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 333. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 334. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 335. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 336. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 337. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 338. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 339. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 340. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 341. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 342. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 343. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
• TABLE 344. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
• TABLE 345. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 346. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 347. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 348. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 349. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 350. SWITZERLAND COMPANION DIAGNOSTICS MA

[194 Pages Report] The Companion Diagnostics Market size was estimated at USD 6.64 billion in 2023 and expected to reach USD 7.30 billion in 2024, at a CAGR 10.65% to reach USD 13.49 billion by 2030.

Companion diagnostics are specialized tests designed to help healthcare professionals determine whether a particular medical treatment is effective for a patient or to identify the best dosage of medication for that individual. These tests are an integral part of personalized medicine, a medical approach that tailors treatment to the individual characteristics of each patient, such as their lifestyle, genetic makeup, and environment. Companion diagnostics are particularly prevalent in the management of certain cancers, where the effectiveness of the treatment can depend significantly on the genetic alterations present within the tumor. The push towards personalized medicine, where treatments are optimized for individual patient profiles, significantly drives the demand for companion diagnostics. Moreover, the development of targeted therapies, especially in oncology, necessitates companion diagnostics to identify patients who would most benefit from these treatments. However, the development and implementation of companion diagnostics can be costly, with inadequate reimbursement posing a significant barrier. Furthermore, technologies, including next-generation sequencing and digital PCR, are expanding the capabilities of companion diagnostics, allowing for more comprehensive genetic profiling poses significant opportunities for market growth.

Technology: Increasing preference of next-generation sequencing in precision medicine

Immunohistochemistry (IHC) is a technique used to diagnose diseases by detecting proteins in tissue section cells. It is widely employed in cancer diagnostics to identify specific markers that help in determining the type of cancer and its potential responsiveness to treatments. IHC is preferred when the diagnostic focus is on the localization and qualitative assessment of protein expressions in tissue samples. Situ Hybridization (ISH) permits the detection and localization of specific DNA or RNA sequences in tissue sections or cell samples, providing insights into gene expression and chromosomal abnormalities. This technology is particularly valuable in detecting specific gene rearrangements or amplifications associated with certain cancers. Next-generation sequencing (NGS) offers comprehensive insights into the genetic makeup by allowing the sequencing of entire genomes or targeted regions of interest at an unprecedented speed and scale. NGS is the technology of choice for applications requiring a broad understanding of genetic variations, including small mutations, copy number variations, and others that may be relevant for selecting targeted therapies across various diseases. Polymerase Chain Reaction (PCR) is a technique utilized to strengthen small segments of DNA or RNA, making it easier to conduct further analyses. It stands as one of the most widely used technologies due to its simplicity, sensitivity, and specificity. PCR is highly favored for its rapid turnaround times, making it ideal for diseases requiring quick decision-making for therapy selection.

End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics

Pharmaceutical and biopharmaceutical companies engaged primarily in the discovery, development, and commercialization of therapeutics. The integration of companion diagnostics is crucial in the drug development process, especially for targeted therapies, including those used in cancer treatment. These companies need companion diagnostics to monitor responses to therapy and adjust treatment plans as necessary. Reference laboratories are specialized facilities that perform complex and advanced diagnostic testing, often not available in standard hospital labs. They play a critical role in the implementation of companion diagnostics by providing high-complexity tests that help in the identification of biomarkers associated with specific diseases and treatment responses.

Regional Insights

In the Americas, the demand for companion diagnostics is driven by a robust healthcare infrastructure, heightened awareness about personalized medicine, and significant research and development activities. The U.S. Food and Drug Administration (FDA) has been proactive in approving companion diagnostics, especially for cancer treatments, which underscores the importance of these tools in therapeutic decisions. Investments and initiatives in this region are primarily focused on oncology, cardiovascular diseases, and neurology, reflecting a broader trend toward personalized healthcare solutions. EU countries exhibit a high demand for companion diagnostics, supported by a strong regulatory framework that promotes innovation while ensuring patient safety. The European Medicines Agency (EMA) plays an vital role in the approval of companion diagnostics across Europe. Consumer needs in the EU are sophisticated, with a high expectation for personalized healthcare services. Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, are witnessing a growing interest in personalized medicine, which is supported by government initiatives and investments in healthcare infrastructure. Africa, however, faces significant hurdles due to limited healthcare infrastructure and access. In APAC, the market for companion diagnostics is expanding swiftly, fueled by government initiatives aimed at improving healthcare standards and embracing personalized medicine. The government has launched several initiatives to promote precision medicine, including significant investments in genetic research. This focus is gradually translating into increased demand for companion diagnostics, particularly in urban areas with better healthcare facilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Companion Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Immunohistochemistry
  • In Situ Hybridization
  • Next-Generation Sequencing
  • Polymerase Chain Reaction

• Indication
  • Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer

• Cardiovascular Diseases
• Infectious Diseases
• Neurological Disorders

• End-user
  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Companion Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Companion Diagnostics Market?

4. What is the market share of the leading vendors in the Companion Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Companion Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing significance of companion diagnostics in drug development
    • 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
    • 5.1.1.3. Rise in research and development for innovation in next generation sequencing
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with development and implementation of companion diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements in diagnostic techniques
    • 5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
  • 5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Companion Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Immunohistochemistry
• 6.3. In Situ Hybridization
• 6.4. Next-Generation Sequencing
• 6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular Diseases
• 7.4. Infectious Diseases
• 7.5. Neurological Disorders

8. Companion Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Pharmaceutical & Biopharmaceutical Companies
• 8.3. Reference Laboratories

9. Americas Companion Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Companion Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Companion Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
  • 12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
  • 12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne(R) CDx Diagnostic Advances
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio